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APRESENTAÇÃO 
 
 
 Nesta tese de mestrado, realizada com apoio financeiro da CAPES e da FAPESP (05/60330-8), 
intitulada “EXPRESSÃO DO GENE NR4A1 EM CARCINOMAS DA TIRÓIDE E SEU PAPEL 
POTENCIAL NA TERAPIA DO CÂNCER” apresentamos, de acordo com as recomendações da 
comissão especial do programa de Pós-Graduação em Endocrinologia da Universidade Federal de São 
Paulo (UNIFESP), um trabalho em forma de manuscrito que será submetido à revista Clinical 
Endocrinology. 
 O trabalho foi desenvolvido no laboratório de Endocrinologia Molecular da UNIFESP. Por 
orientação do Prof. Dr. Rui Maciel e da Profª Dra Janete Cerutti, estabelecemos como foco os tumores 
foliculares da tiróide, em particular o perfil de expressão gênica de suas células tumorais. A partir das 
bibliotecas geradas através da técnica SAGE, trabalho este da Profª Drª Janete Maria Cerutti, em 
colaboração com o Prof. Dr. Gregory J. Riggins, pudemos selecionar genes candidatos ao estudo (1). 
Todas as bibliotecas de Tags geradas estão disponíveis no site do Cancer Genome Anatomy Project 
(CGAP) para download ou análise - http://cgap.nci.nih.gov/SAGE. 
 Identificamos genes cuja expressão estava diminuída nas bibliotecas de carcinoma folicular de 
tiróide (FTC): TPO, TFF3, NR4A1 e IYD. O NR4A1 foi selecionado para uma análise mais profunda, 
por apresentar expressão potencialmente tecido-específica. Passamos então à validação do padrão 
diferencial de expressão em tecidos neoplásicos e não-neoplásicos, pela técnica de PCR em tempo real, 
assim como a realização de experimentos em linhagens celulares, com o uso de lítio. Estes são os focos 
desta tese e estão descritos no manuscrito “Downregulation of NR4A1 in follicular thyroid 
carcinoma cell line is restored after lithium treatment”. 
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 Durante todo o período em que estive desenvolvendo esta pesquisa, acompanhei e participei de 
vários outros trabalhos de teses relacionados com doenças malignas e benignas da tiróide e que 
resultaram em publicações onde sou co-autor (2-5).  
 Reis EM, Ojopi EP, Alberto FL, Rahal P, Tsukumo F, Mancini UM, Guimarães GS, 
Thompson GM, Camacho C, Miracca E, Carvalho AL, Machado AA, Paquola AC, Cerutti 
JM, da Silva AM, Pereira GG, Valentini SR, Nagai MA, Kowalski LP, Verjovski-Almeida 
S, Tajara EH, Dias-Neto E, Bengtson MH, Canevari RA, Carazzolle MF, Colin C, Costa FF, 
Costa MC, Estécio MR, Esteves LI, Federico MH, Guimarães PE, Hackel C, Kimura ET, 
Leoni SG, Maciel RM, Maistro S, Mangone FR, Massirer KB, Matsuo SE, Nobrega FG, 
Nóbrega MP, Nunes DN, Nunes F, Pandolfi JR, Pardini MI, Pasini FS, Peres T, Rainho CA, 
dos Reis PP, Rodrigus-Lisoni FC, Rogatto SR, dos Santos A, dos Santos PC, Sogayar MC, 
Zanelli CF; Head and Neck Annotation Consortium. 2005 Large-scale transcriptome 
analyses reveal new genetic marker candidates of head, neck, and thyroid cancer. Cancer 
Res 65:1693-9 
 Biscolla RP, Ikejiri ES, Mamone MC, Nakabashi CC, Andrade VP, Kasamatsu TS, Crispim 
F, Chiamolera MI, Andreoni DM, Camacho CP, Hojaij FC, Vieira JG, Furlanetto RP, 
Maciel RM. 2007 [Diagnosis of metastases in patients with papillary thyroid cancer by the 
measurement of thyroglobulin in fine needle aspirate]. Arq Bras Endocrinol Metabol 
51:419-25 
 Guimaraes GS, Latini FR, Camacho CP, Maciel RM, Dias-Neto E, Cerutti JM 2006 
Identification of candidates for tumor-specific alternative splicing in the thyroid. Genes 
Chromosomes Cancer 45:540-53 
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 Tamanaha R, Camacho CP, Ikejiri ES, Maciel RM, Cerutti JM 2007 Y791F RET mutation 
and early onset of medullary thyroid carcinoma in a Brazilian kindred: evaluation of 
phenotype-modifying effect of germline variants. Clin Endocrinol (Oxf) 67:806-8 
 
Também participo de outros trabalhos como co-autor que estão aceitos para publicação ou submetidos 
à publicação: 
 Gisele Oler, Cléber P. Camacho, Flávio C. Hojaij, Pedro Michaluart Jr., Gregory J. 
Riggins and Janete M. Cerutti. Gene Expression Profiling of Papillary Thyroid Carcinoma 
Identifies Transcripts that Are Correlated with BRAF Mutational Status and Lymph Node 
Metastasis. Aceito para publicação, Clinical Cancer Research.  
 Helton E. Ramos, Leando A. Diehl, Cléber P. Camacho, Petros Perros, Hans Graf. 
“Management of Graves’ Orbitopathy in Latin America: an International Questionnaire 
Study compared with Europe”. Aceito para publicação, Clinical Endocrinology 
 Rosana Tamanaha, Cléber P. Camacho, Alexandre C. Pereira, Adriana M. Álvares da 
Silva, Rui M.B. Maciel and Janete M. Cerutti. Evaluation of RET polymorphisms in a six-
generation family with G533C RET mutation: specific RET variants may modulate age at 
onset and clinical presentation. Submetido à revista The Journal of Clinical 
Endocrinology and Metabolism. 
 Ricardo A. Guerra, Felipe Crispim, Cláudia C. D. Nakabashi, Cleber P. Camacho, 
Teresa S. Kasamatsu, Rui M. B. Maciel. "Thyroglobulin is still detectable in the serum of 
normal individuals after a trial of TSH-suppressive doses of L-T4 during 3 months". 
Submetido à revista Thyroid 
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 Helton E. Ramos, Valter T. Boldarine, Suzana Nesi-França, Cleber P. Camacho, 
Gustavo S. Guimarães, Magnus R. Dias da Silva, Hans Graf, Luiz de Lacerda, Gisah A. 
Carvalho, Rui M. B. Maciel. "NKX2.5 missense mutations are associated with thyroid 
ectopy: a study of 157 patients with thyroid dysgenesis". Submetido à revista Journal of 
Clinical Endocrinology and Metabolism  
 Helton E. Ramos, Suzana Nesi-França, Valter T. Boldarine, Rosana M. Pereira, Maria 
Izabel Chiamolera, Cleber P. Camacho, Hans Graf, Luiz de Lacerda, Gisah A. Carvalho, 
Rui M. B. Maciel. "Clinical and Molecular Analysis of Thyroid Hypoplasia: A 
Population-based Approach in Southern Brazil". Submetido à revista Thyroid. 
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INTRODUÇÃO 
 
 As neoplasias malignas da tiróide são as neoplasias endócrinas mais comuns (90%) e 
respondem por mais da metade das mortes por cânceres endocrinológicos. O uso da ultra-sonografia na 
avaliação da doença nodular da tiróide foi de extrema importância ao auxiliar o diagnóstico precoce 
destas neoplasias, mas ao mesmo tempo gerou um grande problema, já que aumentou a incidência de 
nódulos tiroidianos para até 67% (6). 
 Este aumento da incidência dos nódulos tiroidianos teve duas conseqüências inevitáveis: o 
aumento do número de citologias aspirativas com agulha fina (CAAF) com diagnóstico indeterminado 
e o aumento na incidência da neoplasia maligna da tiróide, basicamente pelo aumento da detecção de 
carcinomas papilíferos pequenos (7). 
 Até o momento, os diagnósticos indeterminados representam 10 a 20% das CAAF. A incapacidade 
diagnóstica dos métodos tradicionais, particularmente da CAAF (8), gerou uma corrida dos centros de 
pesquisa por métodos alternativos que conseguissem aumentar a sensibilidade e especificidade de tal 
citologia. 
 Mesmo antes desta “epidemia relativa” de cânceres de tiróide, já se pesquisavam os mecanismos 
responsáveis pela gênese das neoplasias malignas da tiróide (9, 10). Assim, dentre os eventos 
relacionados com a gênese do câncer tiroidiano, identificou-se o gene RET, que codifica uma proteína 
cinase transmembrana, a qual, através do rearranjo com outros genes, é relacionada com a gênese do 
carcinoma papilífero da tiróide. Além disso, a mutação ativadora do RET foi relacionada com a gênese do 
carcinoma medular da tiróide. Recentemente, identificou-se a mutação V600E no BRAF como sendo o 
evento responsável pela maioria dos casos de carcinoma papilífero.  
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 No entanto, o maior desafio cerca o carcinoma folicular da tiróide (FTC), que apresenta as 
características de célula tiroidiana diferenciada, mas que não evidencia alterações nucleares 
características do carcinoma papilífero da tiróide, as quais permitem o diagnóstico deste subtipo através 
da CAAF. Seu diagnóstico tem sido realizado apenas histologicamente, depois da cirurgia, por meio da 
identificação de invasão tumoral da cápsula, dos vasos ou do tecido tiroidiano adjacente, o que o 
diferencia do adenoma folicular da tiróide (FTA), lesão benigna. O FTC pode responder por até 50% 
dos tumores diferenciados da tiróide, com maior freqüência em regiões carentes de iodo (11). 
 O FTC pode se apresentar sob duas formas: uma minimamente invasiva (MIFC) e a outra 
extensamente invasiva (WIFC). A MIFC apresenta um prognóstico semelhante ao do FTA, sendo 
necessária avaliação criteriosa por parte do patologista, para que este subtipo seja corretamente 
classificado. O WIFC é mais facilmente diferenciado das lesões benignas. Mesmo na forma WIFC, é 
extremamente rara a ocorrência de metástase para linfonodos cervicais, sendo observadas, em 5 a 20% 
dos casos, metástases à distância, principalmente para pulmões e ossos. 
 Vários fatores moleculares foram até agora apontados como participantes da patogênese do 
FTC, mas nenhum deles pode ser considerado como sua causa predisponente principal (10). Assim, 
mutações ativadoras do oncogene RAS são conhecidas há algum tempo e estão presentes em 
aproximadamente 40% dos FTC, mas podem ser encontradas também em até 20% do FTA e em 10% 
dos carcinomas papilíferos da tiróide (12).  
Kroll e cols. nos levaram a acreditar que o desafio de identificar um evento responsável por esta 
neoplasia havia chegado ao fim (13). No entanto, o rearranjo do PAX8 e do PPARγ também foi 
encontrado em neoplasias benignas da tiróide (14). Ying e cols. geraram o primeiro modelo animal de 
carcinoma folicular da tiróide através de uma mutação no receptor do hormônio tiroidiano (15). 
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 Apesar da fisiopatologia do FTC continuar desconhecida, Cerutti e cols. conseguiram identificar 
4 novos marcadores: DDIT3, ARG2, ITM1 e Clorf24, que, quando usados em combinação, são capazes 
de distinguir as lesões adenoma folicular de carcinoma folicular com alta sensibilidade e especificidade 
(1). Estudo posterior demonstrou que tais marcadores distinguem outras lesões da tiróide comumente 
classificadas como padrão folicular (16) e, desta forma, representaram um grande passo na questão das 
CAAF indeterminadas, além de ser uma pista importante na determinação das vias envolvidas na 
patogênese do carcinoma folicular da tiróide. 
 O tratamento atual dos tumores diferenciados da tiróide é baseado na realização da 
tiroidectomia total e da radioiodoterapia, sendo eficiente na grande maioria dos casos. No entanto, 
naqueles pacientes em que estes procedimentos não foram capazes de alcançar a cura, a radioterapia 
externa e a quimioterapia são os procedimentos alternativos existentes e apresentam resultados 
variáveis. O lítio e o ácido retinóico são usados como adjuvantes ao radioiodo, sendo observados 
resultados insatisfatórios. A pesquisa com novas drogas para alvos moleculares é uma nova esperança, 
mas no caso do FTC, ainda não foram identificados tais alvos (17). 
 Neste contexto, iniciamos a busca por genes diferencialmente expressos que pudessem ser 
avaliados em modelos experimentais e que tivessem um papel potencial na terapia do câncer, sendo 
este o enfoque do manuscrito a seguir. 
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OBJETIVOS 
 
 
1) Validar a expressão de NR4A1 nos tecidos benignos e malignos da tiróide.  
2) Avaliar a correlação dos genes CCND1 e FOSB com a expressão de NR4A1. 
3) Verificar a expressão dos genes NR4A1, CCDN1 e FOSB nas linhagens de carcinoma tiroidiano 
disponíveis no laboratório, com objetivo de indetificar um modelo semelhante a expressão observada 
nos tecidos.   
4) Verificar se a expressão dos genes NR4A1, FOSB e CCDN1 poderia ser restabelecida quando 
tratadas com lítio.   
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Abstract 
 
Introduction: The identification of follicular thyroid adenoma-associated transcripts will lead to a better 
understanding of the events involved in pathogenesis and progression of follicular tumors. Using Serial Analysis 
of Gene Expression, we identified five genes that are absent in a malignant follicular thyroid carcinoma (FTC) 
library, but expressed in follicular adenoma (FTA) and normal thyroid libraries.  
Methods: NR4A1, one of the five genes, was validated in a set of 27 normal thyroid tissues, 10 FTAs and 14 
FTCs and three thyroid carcinoma cell lines by real time PCR. NR4A1 can be transiently increased by a variety 
of stimuli, including lithium, which is used as adjuvant therapy of thyroid carcinoma with 
131
I. We tested if 
lithium could restore NR4A1 expression. The expression of other genes potentially involved in the same 
signaling pathway was tested. To this end, lithium was used at different concentration (10mM or 20mM) and time 
(2h and 24 h) and the level of expression was tested by quantitative PCR. We next tested if Lithium could affect 
cell growth and apoptosis. 
Results: We observed that NR4A1 expression was under-expressed in most of the FTCs investigated, compared 
to expression in normal thyroid tissues and FTAs. We also found a positive correlation between NR4A1 and 
FOSB gene expression. Lithium induced NR4A1 and FOSB expression, reduced CCDN1 expression, inhibited 
cell growth and triggered apoptosis in a FTC cell line.  
Conclusions: NR4A1 is under-expressed in most of FTCs. The loss of expression of both NR4A1 and the Wnt 
pathway gene FOSB was correlated with malignancy. This is consistent with the hypothesis that its loss of 
expression is part of the transformation process of FTCs, either as a direct or indirect consequence of Wnt 
pathway alterations. Lithium restores NR4A1 expression, induces apoptosis and reduces cell growth. These 
findings may explain a possible molecular mechanism of lithium’s therapeutic action.   
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Introduction 
 
The number of thyroid cancer cases is increasing and for women this malignancy has one of the highest 
rates of increased incidence in the United States. Papillary thyroid carcinoma (PTC) and follicular thyroid 
carcinoma (FTC) are the most frequent thyroid cancer subtypes
1 
. During the last two decades we have seen 
progress in our understanding of the molecular biology of these cancers. The importance of the MAPK pathway 
has been identified in PTC, resulting from RAS/BRAF mutations or rearrangements of the RET oncogene 
2-4 
. 
Less is known about the molecular events underlying FTC.  
The most frequent genetic alterations in FTC comprise point mutations of the RAS genes and PAX8-
PPARγ rearrangements. Although they were initially proposed as potentially associated with pathogenesis of 
FTC, these genetic events also occur with significant prevalence in FTA
5-9 
.Although it has been suggested that 
those FTAs with PAX8-PPARγ are more likely to transform into a malignant tumor
10, 11 
, to date there is no 
compelling in vitro or in vivo evidence. Moreover, a high proportion of FTCs are negative for the rearrangement
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and, therefore, unrevealed genes or pathways may be involved in the pathogenesis of this type of thyroid tumor.   
The identification of novel FTA-associated transcripts, could lead to a better understanding of the events 
involved in pathogenesis and progression of FTC. We compared the gene expression profiles of three SAGE 
libraries generated from thyroid tumors and a normal thyroid tissue
12, 13 
. The expression analysis was performed 
originally to locate clinical markers and the data are posted at http://cgap.nci.nih.gov/SAGE. Using SAGE 
Digital Gene Expression Displayer (DGED), a tool to compare SAGE libraries, we identified five genes that are 
expressed in normal thyroid and FTA but not expressed in the malignant FTC. One of these genes, NR4A1, 
encodes an orphan member of the steroid/thyroid/retinoid super-family, whose members act mainly as 
transcription factors that induce or repress gene expression
14 
. NR4A1 (Nuclear receptor subfamily 4, group A, 
member 1) was of particular interest because it was under-expressed in several tumors compared with the 
corresponding normal tissues
15, 16 
 and because NR4A1 appears to up-regulate pro-apoptosis genes
17, 18 
.  
Consequently, one can hypothesized that lost or reduced NR4A1 expression in tumors may be associated 
with malignant transformation of follicular thyroid cells. Although the mechanisms involved in the
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transcriptional regulation of NR4A1 is not completely understood, it was described as a target of Wnt-1 
(Wingless-type MMTV integration site family, member 1
16 
. The best understood Wnt pathway is the canonical 
pathway, which controls cell proliferation through inhibition of glycogen synthase kinase-3 beta (GSK3β) and 
increase in transcriptional activation of β-catenin targets. Although the authors described NR4A1 as a Wnt-1 
responsive gene with decreased expression in tumors, they suggested that NR4A1 may be up-regulated by a 
noncanonical Wnt signaling pathway
16 
.  
NR4A1 was also of interest because its expression can be transiently increased by a variety of stimulus, 
including lithium a drug that has been used to therapy of thyroid cancer
16, 19-21 
. It was shown that lithium acts as 
a specific inhibitor of the glycogen synthase kinase-3 beta (GSK3β). Although Lithium has been used as 
adjuvant to the 
131
I therapy of thyroid cancer, the cellular target of lithium is still unknown.   
We investigated the expression of NRA41 in a set of normal thyroid tissues, FTAs and FTCs. 
Subsequently, we investigated the level of expression of other genes downstream the Wnt signaling pathway and 
correlate their expression with NR4A1 expression. We next sought to test whether lithium could restore the 
NR4A1 expression in thyroid cell lines and explain a possible molecular mechanism for the effect of lithium as 
an adjuvant therapy for thyroid cancer.   
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Material and Methods 
SAGE Digital Gene Expression Displayer. DGED was used to identify genes differentially expressed between 
benign (normal tissue and FTA) and malignant (FTC) SAGE libraries. The full set of tag counts for all thyroid 
libraries is available for downloading or analysis at the Cancer Genome Anatomy Project SAGE Genie Web site 
(http://cgap.nci.nih.gov/SAGE)
12 
. To identify genes differentially expressed, we defined as criteria P <0.05 and 
10-fold difference in the level of expression between the two groups (Fig. 1).  
Tissue Specimens. A total of 41 thyroid tissue specimens obtained from patients undergoing thyroid surgery for 
thyroid disease at Hospital São Paulo, Federal University of São Paulo, Brazil, were used in this study. Samples 
were frozen immediately after surgery and stored at -80°C and included 27 normal thyroids (NTs) 10 FTAs and 
14 malignant (FTCs) tissues.  Among 14 FTCs, 6 were classified as widely invasive follicular thyroid tumors 
(WIFC) (capsular and vascular invasion and extension of the tumor beyond the thyroid gland). All tissue 
samples were obtained with informed
 
consent according to established Human Studies Protocols at Federal 
University of São Paulo. The study of patient materials was conducted according to the
 
principles expressed in 
the Declaration of Helsinki.  
Cell Lines. A FTC (WRO), PTC (NPA) and an undifferentiated thyroid carcinoma (ARO) cell lines used in this 
study were previously characterized
22-25 
. Cell lines were grown in DMEM (Invitrogen Corp., Carlsbad, CA) 
supplemented with 10% FBS (Invitrogen), with 100 units/mL of penicillin and 100 µg/mL streptomycin
 
in a 
humidified incubator containing 5% CO2 at 37ºC as described
26, 27 
.   
RNA extraction and cDNA synthesis and quantitative PCR (qPCR). Total RNA isolation and cDNA synthesis 
were performed as previously reported
13 
. Briefly, one microgram of total RNA was treated with a DNAse 
(Ambion, Austin, TX) and was reverse-transcribed to cDNA using Super-Script II Reverse Transcriptase kit with 
an oligo(dT)12-18 primer and 10 units of RNase inhibitor (Invitrogen). An aliquot of cDNA was used in 20µL 
PCR reaction containing SYBR Green PCR Master Mix and 200 nM of each primer for the target (NR4A1, 
CCDN1 and FOS) or reference genes (ribosomal protein S8 and QPC). Primers were designed using Primer3 
software (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi). The PCR reaction was performed for 40 
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cycles of a 4-step program: 94
o
C for 15 sec, annealing temperature for 20 sec, 72
o
C for 20 sec, and a 
fluorescence-read step for 20 sec. qPCR reactions were performed in triplicate. The threshold cycle (Ct) was 
obtained using Applied Biosystem software and was averaged (SD ≤1). Gene expression was normalized using 
the average of 2-reference genes. Fold changes were calculated as previously described
28 
.   
NR4A1, FOSB and CCDN1 Expression after Lithium Treatment. 5 × 10
6
 cells WRO cells were plated in 35mm 
plates. After 24 hours, cells were harvest with fresh medium containing lithium chloride (LiCl; Sigma-Aldrich 
Corp. St. Louis, MO, USA). Concentration (10mM  and 20mM) and time (2 and 24 hours) were determined 
according to previous studies
16, 29 
. Doses of 10mM and 20mM lithium are commonly used to achieve GSK3β 
inhibition and activation of Wnt/β-catenin signaling
29
. Total RNA isolation, cDNA synthesis and qPCR for 
NR4A1, FOSB, CCDN1 and reference genes were performed as described above. Additionally, the Sodium-
Iodide-Symporter (NIS) expression was tested following lithium treatment.  
MTT Assay. We next investigated the effect of lithium on cell proliferation. In brief, 2 x 10
4
 WRO cells were 
seeded
 
in 35-mm in quintuplicate, allowed to adhere overnight, and then treated with lithium at 10mM and 20mM 
concentrations. At each time point, cell growth rates were analyzed following addition of 3,4-(4,5-
dimethylthiazol-2-yl)-2.5-diphenyltetrazolium bromide (MTT) (Sigma) reagent to the cultured cells as 
described
30 
. Absorbance was measured using spectrophotometer at a wavelength of 560 nm. 
Apoptosis Assay. We investigated if lithium could induce apoptosis in WRO cells. Briefly, 2 × 10
4
 cells WRO 
cells were plated in 35mm plates in quintuplicate. Cells were then treated with lithium at 10mM and 20mM 
concentrations. At indicated time, Annexin V–positive cells were measured using the Guava Nexin kit as 
described
30 
. 
Statistical Analysis. qPCR values were log-transformed before application of statistical tests. Unpaired student t 
test was used to examine differences between two groups and ANOVA with Bonferroni correction was used to 
examine differences among groups (StatView software). To test the significance of the relationship between 
genes, Pearson correlation was used. Chi-squared (X
2
) with odds ratio (OR) was performed to determine the risk 
for tumorigenesis. A P value of < 0.05 was considered significant.  
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Results 
Genes Potentially Associated with Pathogenesis of Thyroid tumors. Differentially expressed genes can be found 
by comparison of various SAGE libraries using the SAGE Digital Gene Expression Display (SAGE DGED)
31 
. 
We compared two pools of thyroid SAGE libraries. Pool A included both normal thyroid and FTA and pool B 
consisted of FTC library. Using P <0.05 as the value for statistical significance and 10-fold as the difference in 
the level of expression, we identified 6 transcripts differentially expressed between pool A and pool B. Our 
primary focus was on genes whose expression was lower in FTC library such as TPO, TFF3, NR4A1, and IYD 
(Fig. 1). NR4A1 was selected for further investigation. 
NR4A1 Expression in Thyroid Tissues. The data predicted by SAGE was validated by qPCR using a set of 27 
normal thyroid tissues, 10 FTAs and 14 FTCs. We observed that NR4A1 expression was under-expressed in most 
FTCs investigated (65%), compared with the expression observed in normals (P=0.01) and FTAs (Fig. 2A). The 
expression was remarkably lower in widely invasive follicular carcinoma than adenoma (P=0.02) (Fig. 2B). To 
determine the risk of tumorigenesis, the level of NR4A1 expression was analyzed in FTCs (n=14) and normal 
thyroid (n=22) groups. Using 0.1 as the cutoff value, expression levels lower than 0.1 were observed in 5 of 22 
normal thyroids and 8 of 14 FTCs. A low level of NR4A1 expression was associated with an increased risk of 
FTC (Odds ratio= 5.8; χ
2
:6,352; P = 0.0117; IC95%: 1.39 – 24.67). To provide a more accurate estimate of the
 
risks of malignancy associated with NR4A1 level of expression, a larger series and absolute values are needed.  
FOSB and CCND1expression in thyroid Samples. Since NR4A1 was suggested as downstream of Wnt-1 
signaling pathway, we investigated the expression of canonical Wnt-1 target genes such as FOSB and CCDN1. 
Additionally, we sought to determine whether there is a correlation among expression levels for NR4A1, FOSB 
and CCND1.  
FOSB was under-expressed in most of thyroid carcinomas and a number of FTAs compared to normal 
thyroid, although not significant (Fig.  2C). Intriguingly, CCDN1 was over-expressed in both FTCs (P < 0.01) 
and FTAs (P = 0.01), compared to normal thyroid (Fig. 2D).     
12 
 
We found a positive correlation between NR4A1 and FOSB genes in normal tissue (P= 0.0065), 
adenoma (P= 0.0429) and carcinoma tissue (P= 0.0020) (Fig. 2E). There was no correlation between NR4A1 and 
CCND1 (Fig. 2F).  
Lithium restores NR4A1 and FOSB expression and reduced CCND1 expression in FTC cell line. We next 
investigated expression levels of NR4A1, CCND1 and FOSB in thyroid carcinoma cell lines: NPA, ARO and 
WRO. NR4A1 and FOSB were under-expressed in all cell lines compared to normal thyroid. CCND1 was over-
expressed in WRO, compared to normal thyroid (Fig. 3A, B and C). Since the WRO follicular thyroid carcinoma 
cell line had patterns expression of the tested genes similar to those observed in FTCs, it was selected for further 
analysis.    
WRO cells were cultured in medium containing Lithium Chloride (LiCL) at different concentrations and 
time and the level of expression of selected genes were determined. In multiple experiments, qPCR
 
analysis 
showed a consistent increased of NR4A1 transcripts in 2h lithium-treated cells compared with
 
untreated controls, 
in a dose-dependent manner. A greater effect was observed when cells were treated with 20 mM LiCl for 2 h (Fig 
4A). After 24 h, NR4A1 expression was up-regulated only at high doses of lithium (Fig 4B). The expression of 
FOSB, an early gene, was restored after 2 h treatment when 20 mM lithium was used and was down-regulated in 
cells exposed to 10 mM LiCl for 2 h (Fig. 4C and D). FOSB was down-regulated in and 24 h lithium-treated cells 
compared with
 
untreated controls, in a dose-dependent manner (Fig. 4D).  
The expression of CCND1 was biphasic with a slight increase at 2 h of lithium treatment followed by a 
down-regulation at 24 h as compared with untreated control cells. Comparable effects of lithium on CCND1 
expression were previously reported
32 
 (Fig.  4E and 4F). 
Since lithium has been suggested to act as an adjuvant to 
131
I therapy by inhibiting its release from the 
thyroid, we tested whether the expression of the sodium-iodide symporter (NIS) changed after lithium treatment. 
We did not find any difference in expression of NIS in WRO-treated cells compared with non-treated controls 
(data not shown).   
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Lithium inhibits cell growth and induces apoptosis in FTC cell line. Although controversy, previous studies 
showed that over-expression of NR4A1 inhibited cell growth and induced apoptosis. Since lithium restores 
NR4A1 expression in FTC cell line, we investigated the effect of lithium on cell growth and apoptosis. As 
showed in Fig. 5A, lithium treatment resulted in a progressive and dose-dependant cell growth inhibition as 
compared with the untreated control cells. The reduction in cell proliferation in 20 mM lithium treated cells was 
statistically significant in all treatment points compared to control cells (P<0.001). To quantify
 
the apoptotic rate 
of WRO cells following treatment, different concentration of lithium were tested at 48 and 72 hours, a time in 
which growth inhibition was more evident for both concentrations. Lithium significantly increased the number 
of apoptotic
 
cells in a time and dose-dependent manner (P<0.001) (Fig. 5B).  
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Discussion  
In this study, using SAGE Digital Gene Expression Display and validation by qPCR, we found that 
NR4A1 was under-expressed in most of FTCs compared to normal thyroid and FTA, and markedly lower in 
widely invasive follicular thyroid carcinoma.   
NR4A1, also known as Nur77, TR3 and NGFI-B, an orphan nuclear receptor, was first described as an 
immediate early gene induced in response to serum or phorbol ester stimulation of quiescent fibroblasts. 
Although it was initially known for its role in cell proliferation and differentiation, later was shown to be a 
potent pro-apoptotic molecule in different cell types. Inhibition of NR4A1 activity either by
 
over-expressing a 
dominant-negative form or using antisense RNA, inhibited apoptosis
33, 34 
. Consistent with its apoptotic activity, 
over-expression of NR4A1 in some cell lines leads to apoptosis. It was demonstrated that its apoptotic activity 
can be altered through AKT-mediated phosphorylation in the DNA binding domain of NR4A1 and substantially 
diminishes its ability to bind DNA and diminish its apoptotic activity
35 
. Others have suggested that NR4A1 is 
phosphorylated through the ERK5 pathway
36 
. Moreover, it was suggested that NR4A1-mediated apoptosis 
involves transcription-independent mitochondrial targeting of NR4A1. When induced by apoptotic stimuli, 
NR4A1 translocates into the cytoplasm where it binds to Bcl2 and provokes conformational
 
change of Bcl2. This 
results in conversion
 
of Bcl2 from a cell protector to a cell killer
37, 38 
.  
Based on its apoptotic effects, many studies were performed searching for a link between tumorigenesis 
and NR4A1 expression. NR4A1 expression was reduced in several tumor subtypes compared to normal matched 
samples
16 
. Recently it was described that down-regulation of NR4A1 was a common feature in leukemia blast 
cells from human acute myeloid leukemia (AML)
39 
. Additional evidence that supports a role for NR4A1 in 
tumorigenesis comes from the observation that NR4A1 abrogation in mice led to a rapidly lethal and 
transplantable leukemic disease with pathological features most closely resembling AML. Based on these 
findings, it was suggested a new role of NR4A1, a critical tumor suppressor of myeloid leukemogenesis
39 
.  
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The aforementioned evidences of its potential role as a tumor suppressor gene and the fact that we found 
a decreased expression of NR4A1 in follicular thyroid carcinomas compared to normal thyroid and FTA, suggest 
that the down-regulation of NR4A1 expression might be an important event during thyroid tumorigenesis.   
Given that NR4A1 induction is regulated by a variety of cell- and stimulus-specific such as growth 
factors, calcium, inflammatory cytokines, peptide hormones, phorbol esters, neurotransmitters and lithium
16, 19, 40
, 
we hypothesize whether these agents could restore the expression of NR4A1. 
The effect of lithium on thyroid was first observed in patients who received lithium for mood diseases 
and developed goiter
41 
. Later it was demonstrated that lithium inhibits the release of radioiodine from the 
thyroid
42 
. Due to this effect lithium is considered an option for adjuvant treatment with radioiodine for selected 
cases of thyroid cancers
21, 43, 44 
.  
Based on the fact that lithium has been used as therapeutic drug for thyroid carcinomas for several years 
but it therapeutic action remains an enigma and that it induces NR4A1 expression
16 
, we hypothesize that lithium 
might exert its therapeutic effect by restoring the expression of NR4A1. We show here that when a follicular 
thyroid carcinoma cell was exposed to 10 mM or 20 mM of lithium, NR4A1 expression increased at significant 
levels after 2 hours of treatment, in a dose-dependent manner.   
Additionally, since NR4A1 over-expression in response to
 
a variety of stimuli and chemotherapeutic
 
agents was
 
involved in growth suppression and apoptosis of many cell types
18, 45 
, we further
 
examined if lithium 
could trigger apoptosis and reduce cell growth in a FTC cell line. We demonstrated here that lithium inhibited 
cell growth and induced apoptosis in a dose dependent manner.  This helps implicate a potential role for NR4A1 
in thyroid cells and therapeutic mechanism of lithium action. However, we do not know yet if induction of the 
cell death pathway by lithium is accompanied by translocation
 
of NR4A1 from the nucleus to the 
cytosol/mitochondria or by post-trascriptional modification by ERK5 or by AKT-mediated phosphorylation. 
These possibilities need further investigation. 
Converse to our observations, it has been reported that 5 mM lithium stimulates proliferation of two 
thyroid carcinoma cell lines (papillary and follicular). The authors suggested that inhibition of GSK3β by lithium 
16 
 
lead to an enhancement of proliferation by increasing the β-catenin levels
29 
 and, therefore, mimic the canonical 
Wnt/β-catenin signaling 
29,46 
. However, it was demonstrated that although the inhibition of the GSK3β pathway 
occurred at concentrations as low as 1 mM lithium, substantial growth inhibition of tumor cells does not appear 
until treatment with 10 mM lithium
47 
. Recently, it was demonstrated that treatment with lithium inhibited growth 
of a medullary thyroid carcinoma cell line (TT) both in vivo and in vitro and that exerts its effect via inhibition of 
the glycogen synthase kinase 3β (GSK3β). Increased concentration of lithium significantly reduced growth of 
TT cells in a dose dependent fashion
48 
. Inhibition of GSK3β by specific inhibitors has shown to reduce tumors 
growth in other cancers including colon, melanoma and glioblastoma
49-51
. Therefore, these conflicting results 
could be explained not only for the different concentrations used but also by the fact that the effect of lithium 
may not be general but cell type specific.  
Since it was described that lithium is able to mimic Wnt signaling
46 
 it was logical to assume that lithium 
could modulate other genes downstream in the canonical Wnt/β-catenin signaling pathway. We therefore, 
investigated whether lithium modulated the expression of previously described Wnt-1 target genes CCND1
52 
 
and FOSB
53 
.  
We observed a rapid and dose-dependent increased expression of FOSB in thyroid cells following 
lithium treatment. The rapid and transient expression of FOSB parallel those observed for NR4A1, suggested 
they may have a similar mechanism of activation. Our results are in accordance with the literature where a 
reduced expression of the immediate early gene FOSB was observed following stimulation of cells by Wnt-1
53 
. 
This study also demonstrated that the expression of FOSB was significant reduced in human colon cancer 
relative to normal tissue
53 
.  
We therefore investigated the expression of FOSB in the set of samples where NR4A1 expression was 
tested. We not only found a reduced expression of FOSB in thyroid tumor compared to normal thyroid but a 
positive correlation with NR4A1.  
CCND1, a reduced expression of CCND1 was observed after 24 h treatment with lithium. 
Kunnimalaiyaan et al.,
48 
 previously demonstrated a decreased expression of CCND1 parallel to the increased 
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expression of cell cycle inhibitors such as p21, p15 and p27 following lithium treatment. Whether lithium 
inhibits GSK3β and restores NR4A1 and FOSB expression and decreases CCND1 expression through the 
canonical Wnt/β-catenin signaling pathway, is still not clear.  
Although CCND1 was over-expressed in follicular tumors, there was no correlation with the expression 
of NR4A1. Of note, CCND1 over-expression and FOSB under-expression were previously described as 
associated with tumorigenesis of papillary thyroid carcinoma
54, 55 
.  
Whether NR4A1 play a role in the pathogenesis of papillary thyroid carcinoma (PTC) is controversy. 
Previous studies using gene expression profiling following expression of genetic events that are hallmarks of 
PTC demonstrated that NR4A1 was among the genes found under-expressed in cells expressing either 
RET/PTC3, RAS or BRAF genetic alteration, although not confirmed by qPCR
56 
. Conflicting evidence is that 
NR4A1 was described as one of the genes induced by RET/PTC3
57 
.   
 In conclusion, we show that NR4A1 is down-regulated in follicular thyroid carcinoma compared to 
normal thyroid and follicular adenomas. This event may be associated with cancer development. The level of 
NR4A1 correlates with FOSB which suggests they may be part of the same signaling pathway. Lithium restores 
the expression of NR4A1 and FOSB and reduced expression of CCND1 which reveals a possible molecular 
mechanism of lithium action. We suggest that this adjuvant to 
131
I therapy modulates NR4A1gene expression. 
Therefore, lithium may be an alternative therapeutic adjuvant mainly in those cases of widely invasive follicular 
thyroid carcinoma.  
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Figure Legends 
Fig. 1. SAGE Digital Gene Expression Displayer (DGED).  The comparison of thyroid SAGE libraries identified 
those genes differentially expressed genes greater than 10-fold with P<0.05.  Pool A includes a normal thyroid 
library and a follicular thyroid adenoma library. Pool B includes a follicular thyroid carcinoma library.  
  
Fig.  2.  Relative expression (RE) analysis of selected genes in thyroid tumors and normal thyroid. Transcripts 
levels were normalized to the average of 2-internal controls. The qPCR data were log transformed for statistical 
analysis. Changes were calculated by comparison of the mean expression value. (A) NR4A1 was down-regulated 
in follicular thyroid carcinoma compared to normal thyroid (P=0.01). (B) The expression of NR4A1 was 
dramatically reduced in widely invasive thyroid carcinoma (WITC) compared to adenoma (P=0.02). (C) 
Although FOSB was down-regulated in follicular carcinomas compared to normal thyroid, it was not considered 
significant (D) CCND1 was over-expressed in both follicular adenoma (P=0.01) and follicular 
carcinoma(P=0.006) compared to normal thyroid. (E) All cases together showing a positive correlation was 
found between the levels of NR4A1 and FOSB. (F) All cases together, showing no correlation between NR4A1 
and CCND1. Expression was significantly different at the 0.05 level (*).   
 
Fig. 3. Relative levels of expression of NR4A1 (A), FOSB (B) and CCND1 (C) determined by qPCR in a 
papillary thyroid carcinoma cell line (NPA), follicular thyroid carcinoma cell line (WRO) and undifferentiated 
thyroid carcinoma cell line (ARO), compared to the expression (mean) observed in normal thyroid.     
 
Fig. 4 Effect of lithium treatment on NR4A1 (A,B) FOSB (C,D) and CCND1 (E,F) expression.  
A follicular thyroid carcinoma cell line (WRO) was treated with LiCl 10mM (L10) and 20mM (L20) for 2 hours 
and 24 hours. Transcripts levels were normalized to the average of 2-internal control and qPCR data are 
averaged from two experiments performed in triplicate. The qPCR data were log transformed for statistical 
analysis. Changes were calculated by comparison of the mean expression value. Expression was considered 
significant when P<0.05 (*) and P<0.01(**).   
 
Fig. 5 Effect of lithium on cell growth (A) and apoptosis (B) in a follicular thyroid cell line (WRO). The effect 
was tested using 10mM (L10) and 20mM (L20). (A) Growth assay by MTT was performed as described in 
material and methods. Lithium significantly reduced cell growth in a dose-dependent manner. The data 
represents the mean ± SD of absorbance at 560 nm of experiments performed in quintuplicate on each of four 
days. (B) To quantify
 
the apoptotic rate of WRO cells following lithium treatment, we
 
analyzed annexin-V 
binding using a Guava Nexin kit as described in material an methods section. The data represents the mean ± SD 
of percentage of apoptotic cells following lithium treatment. An increase of apoptosis was observed in a time and 
dose-dependent manner. Changes were significant when P<0.05 (*) and P<0.001(**).   
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CONCLUSÕES 
 
Este trabalho apresentou a expressão diferencial do gene NR4A1 entre tecidos benignos e 
malignos da tiróide, discutindo sua participação na tumorigênese tiroidiana. 
Foi demonstrada a maior associação do NR4A1 com a forma extensamente invasiva de 
carcinoma folicular da tiróide, sugerindo que a perda da sua expressão tenha também relação com um 
maior grau de agressividade. 
Conseguimos demonstrar uma correlação positiva entre o NR4A1 e FOSB, o que sugere uma via 
de sinalização comum. No entanto, nenhuma correlação foi observada entre o NR4A1 e CCND1 nos 
tecidos humanos.  
Identificamos a linhagem de células WRO como um modelo experimental com o mesmo padrão 
de expressão observado nos tecidos de carcinoma folicular da tiróide, tanto para o NR4A1 quanto para 
FOSB e CCND1. 
A utilização do lítio conseguiu aumentar a expressão do NR4A1, e como esperado também 
aumentou a do FOSB, mas também reduziu a expressão do CCND1. O lítio foi capaz de alterar o 
padrão de expressão dos 3 genes nos tecidos benignos da tiróide. 
 O melhor conhecimento do papel do NR4A1 na tumorigênese, assim como das ações do lítio na 
neoplasia folicular tiroidiana, pode resultar em terapias mais eficazes, para o tratamento dos casos onde 
não houve resposta ao tratamento convencional com cirurgia e radioiodo. 
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